$INTI
Inhibitor Therapeutics, Inc.

2017 Q1 Form 10-K Financial Statement

#000119312517048025 Filed on February 17, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2015 Q4 2015
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.990M $570.0K $2.269M
YoY Change 226.23% -3.39% 50.58%
% of Gross Profit
Research & Development $818.3K $470.0K $1.680M
YoY Change 40.48% 51.61% -30.87%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.813M $1.030M $3.950M
YoY Change 135.51% 14.44% 0.3%
Operating Profit -$2.813M -$3.950M
YoY Change 135.51% 0.3%
Interest Expense $10.00K $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.800M -$1.030M -$3.950M
YoY Change 135.29% 14.44% -0.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.801M -$1.030M -$3.950M
YoY Change 134.53% 14.44% -0.65%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.01 $0.00 -$16.98K
COMMON SHARES
Basic Shares Outstanding 353.4M shares 245.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2015 Q4 2015
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.340M $600.0K $601.5K
YoY Change 1850.0% 62.16% 64.71%
Cash & Equivalents $2.340M $601.4K $601.5K
Short-Term Investments
Other Short-Term Assets $300.0K $34.41K $34.41K
YoY Change 476.73% -64.82% -64.82%
Inventory
Prepaid Expenses $51.04K $34.41K
Receivables
Other Receivables
Total Short-Term Assets $2.641M $635.9K $635.9K
YoY Change 1447.62% 37.34% 37.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $134.3K $250.0K $250.0K
YoY Change -46.3%
Total Long-Term Assets $134.3K $250.0K $250.0K
YoY Change -46.3%
TOTAL ASSETS
Total Short-Term Assets $2.641M $635.9K $635.9K
Total Long-Term Assets $134.3K $250.0K $250.0K
Total Assets $2.775M $885.9K $885.9K
YoY Change 559.73% 91.34% 91.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $339.7K $383.4K $383.4K
YoY Change -47.51% 17.97% 17.97%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $395.8K $461.9K $461.9K
YoY Change -46.76% 15.21% 15.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $395.8K $461.9K $461.9K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $395.8K $461.9K $461.9K
YoY Change -46.76% 15.21% 15.21%
SHAREHOLDERS EQUITY
Retained Earnings -$45.97M -$36.17M
YoY Change 23.03% 12.26%
Common Stock $48.35M $36.60M
YoY Change 30.53% 13.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.379M $424.0K $424.0K
YoY Change
Total Liabilities & Shareholders Equity $2.775M $885.9K $885.9K
YoY Change 559.73% 91.34% 91.34%

Cashflow Statement

Concept 2017 Q1 2015 Q4 2015
OPERATING ACTIVITIES
Net Income -$2.801M -$1.030M -$3.950M
YoY Change 134.53% 14.44% -0.65%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$870.0K -$640.0K -$2.264M
YoY Change 81.25% 23.08% 73.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.500M
YoY Change 66.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.680M 0.000 2.500M
YoY Change -100.0% 49.84%
NET CHANGE
Cash From Operating Activities -870.0K -640.0K -2.264M
Cash From Investing Activities
Cash From Financing Activities -3.680M 0.000 2.500M
Net Change In Cash -4.550M -640.0K 236.3K
YoY Change 847.92% 6300.0% -35.26%
FREE CASH FLOW
Cash From Operating Activities -$870.0K -$640.0K -$2.264M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Assets
Assets
885859
CY2015Q4 us-gaap Assets Current
AssetsCurrent
635859
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3597290
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
245353270 shares
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
353447172 shares
CY2016Q2 dei Entity Public Float
EntityPublicFloat
11622956
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
62079
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
841524
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
245353270 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
36571982
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
60213
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
17850
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
24535
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
383356
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
3597290
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1681549
CY2015Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
996154
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2015Q4 us-gaap Other Sundry Liabilities
OtherSundryLiabilities
52500
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78524
CY2015Q4 us-gaap Liabilities
Liabilities
461880
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
885859
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
461880
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
34414
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
250000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
423979
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-36172538
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00 pure
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2010742
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
353447172 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
353447172 shares
CY2016Q4 us-gaap Assets
Assets
7338095
CY2016Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6400000
CY2016Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
7196519
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6144641
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50167372
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
142721
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
35345
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
297826
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
56685805 shares
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
53093902 shares
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6144641
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2995024
CY2016Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
996154
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10307
CY2016Q4 us-gaap Liabilities
Liabilities
308133
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7338095
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
308133
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61097
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141576
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
97500
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
7029962
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.11
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43172755
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
650000 shares
CY2016Q4 hppi Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000
CY2016Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00 pure
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1721485
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
236284
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2269335
CY2015 us-gaap Revenues
Revenues
0
CY2015 us-gaap Interest Paid
InterestPaid
0
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
20950
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1342859
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1458241
CY2015 us-gaap Operating Expenses
OperatingExpenses
3949585
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-3949585
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
186597
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-3949585
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
150981
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2263716
CY2015 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-136332
CY2015 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
90000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1680250
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1721485
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
232616649 shares
CY2015 hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
2500000
CY2015 hppi Issuance Of Common Stock In Payment Of Trade Payable
IssuanceOfCommonStockInPaymentOfTradePayable
90000
CY2015 hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2500000
CY2016 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
3563675
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6283977
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
47924
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4380695
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 us-gaap Revenues
Revenues
0
CY2016 us-gaap Interest Paid
InterestPaid
0
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
74355
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2380073
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2547351
CY2016 us-gaap Operating Expenses
OperatingExpenses
7022202
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-7000217
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
168259
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-7022202
CY2016 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21985
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10042525
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
558000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-153747
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3758548
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-241633
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2664900
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <b><i>Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2016 us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized.
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2664900
CY2016 dei Trading Symbol
TradingSymbol
HPPI
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2641507
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y11M27D
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3563675
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
288752723 shares
CY2016 hppi Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
2788500
CY2016 hppi Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
0
CY2016 hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
558000
CY2016 hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2836424
CY2016 hppi Proceeds From Exercise Of Common Stock Warrants Related Party
ProceedsFromExerciseOfCommonStockWarrantsRelatedParty
3983201
CY2016 hppi Issuance Of Common Stock Upon Warrant Exercise To Related Party
IssuanceOfCommonStockUponWarrantExerciseToRelatedParty
3983201
CY2016 hppi Insurance Policy Term Of Tail Coverage
InsurancePolicyTermOfTailCoverage
P6Y

Files In Submission

Name View Source Status
0001193125-17-048025-index-headers.html Edgar Link pending
0001193125-17-048025-index.html Edgar Link pending
0001193125-17-048025.txt Edgar Link pending
0001193125-17-048025-xbrl.zip Edgar Link pending
d306040d10k.htm Edgar Link pending
d306040dex1011.htm Edgar Link pending
d306040dex1016.htm Edgar Link pending
d306040dex106.htm Edgar Link pending
d306040dex231.htm Edgar Link pending
d306040dex311.htm Edgar Link pending
d306040dex312.htm Edgar Link pending
d306040dex321.htm Edgar Link pending
d306040dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20161231.xml Edgar Link completed
hppi-20161231.xsd Edgar Link pending
hppi-20161231_cal.xml Edgar Link unprocessable
hppi-20161231_def.xml Edgar Link unprocessable
hppi-20161231_lab.xml Edgar Link unprocessable
hppi-20161231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending